Fan Y H, Ma H X, Guo S P, Chen Y, Zhang S P
Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Front Oncol. 2022 Apr 21;12:822469. doi: 10.3389/fonc.2022.822469. eCollection 2022.
Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor. This report describes a 20 year-old man with PPES. After 4 neoadjuvant chemotherapy cycles (VACwith alternating IE) combined with anlotinib, the left total pneumonectomy was performed. Then maintenance anlotinib monotherapy was continued, no sign of recurrence to date as an outcome. To our knowledge, this is the first demonstration of anlotinib combined with neoadjuvant chemotherapy efficacy in PPES.
原发性肺尤文肉瘤/原始神经外胚层肿瘤（PPES）极为罕见，且预后较差。肿瘤血管生成在肿瘤发生过程中起着重要作用，因此已成为分子靶向治疗的热点话题。安罗替尼是一种新型口服小分子多靶点受体酪氨酸激酶（RTK）抑制剂。本报告描述了一名20岁的PPES男性患者。在4个周期的新辅助化疗（VAC与IE交替）联合安罗替尼治疗后，实施了左全肺切除术。随后继续进行安罗替尼单药维持治疗，目前尚无复发迹象。据我们所知，这是安罗替尼联合新辅助化疗治疗PPES疗效的首次报道。
